Skip to content
OpenCapital
Get started

Foghorn Therapeutics FHTX Q4 2025 Annual earnings

Reported March 11, 2026 · Before market open

Revenue$9.2MMiss by $904.7K
EPS-$0.34Miss by $0.06
Revenue estimate$10.2M
EPS estimate-$0.28

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$7.0M
EPS estimate-$0.23

Versus estimates

Revenue

Q1 2026$3.3MMiss by $4.7M
Q4 2025$9.2MMiss by $904.7K
Q3 2025$8.2MMiss by $1.3MQ2 2025$7.6MMiss by $616.0KQ1 2025$6.0MMiss by $287.7KQ4 2024$2.9MMiss by $5.8M

Diluted EPS

Q1 2026-$0.29Miss by $0.01
Q4 2025-$0.34Miss by $0.06
Q3 2025-$0.25Beat by $0.06Q2 2025-$0.28Beat by $0.03Q1 2025-$0.30In lineQ4 2024-$0.30Beat by $0.13

Ask the moment Foghorn Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Foghorn Therapeutics report Q4 2025 earnings?
Foghorn Therapeutics (FHTX) reported Q4 2025 earnings on March 11, 2026 before market open.
What were Foghorn Therapeutics's Q4 2025 revenue and EPS?
Foghorn Therapeutics reported revenue of $9.2M and eps of $-0.34 for Q4 2025.
Did Foghorn Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $10.2M by $904.7K. EPS missed the consensus estimate of $-0.28 by $0.06.
How did Foghorn Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 223.8% from $2.9M a year earlier and eps declined 13.3% from $-0.30.
Where can I find Foghorn Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001628280-26-016805) and the 10-K periodic report (0001628280-26-016814) directly on SEC EDGAR. The filing index links above go to sec.gov.